R(+)-SCH-23390 hydrochloride has been used:
- for intraperitoneal injection into experimental rats to study the role of D1 receptor in sensitization
- as a D1 receptor-selective antagonist for intracranial drug infusions
- as an antagonist of D1 receptor to study its effect on learning ability in fish
A selective dopamine D1 receptor antagonist.
Potent D 1 antagonist (K i values are ~ 0.2, 0.3, ~ 1100, ~ 800 and ~ 3000 nM at D 1 , D 5 , D 2 , D 3 and D 4 receptors respectively). Also an agonist at 5-HT 1C/2C receptors (K i = 6.3 nM) in vitro .
R(+)-SCH-23390 hydrochloride is a selective D1 dopamine receptor antagonist. It has greater binding capacity towards 5-hydroxytryptamine 2 (5-HT2) and 5-HT1C serotonin receptor subtypes in in vitro. R(+)-SCH-23390 has a half-life of about 25 minutes after administration. It is known to possess anti-stereotypic effect and cataleptogenic effect. It also has inhibitory effect on motor activity.
SCH-23390 can abolish generalized seizures evoked by the chemoconvulsants. SCH-23390 has also been used in studies of other neurological disorders in which the dopamine system has been implicated, such as psychosis and Parkinson's disease. Apart from the study of neurological disorders, SCH-23390 has been extensively used as a tool in the topographical determination of brain D1 receptors in rodents, nonhuman primates, and humans[1].
SCH-23390 is a very short-acting compound with an elimination half-life of around 25 min following administration of 0.3 mg/kg i.p. in the rat[1].
SCH-23390 augments dopamine-induced ductus constriction in CD-1 mouse vessels under newborn O2 conditions[5].
D1 Receptor: 0.2 nM (Ki); D5 Receptor: 0.3 nM (Ki); 5-HT2C Receptor: 9.3 nM (Ki); GIRK: 268 nM (IC50)
